Estimating the direct effect of a treatment on an outcome is often the focus of epidemiological and clinical research, when the treatment has more than one specified pathway to the defined outcome. Even if the total effect is unconfounded, the direct effect is not identified when unmeasured...

Issues of post-randomization selection bias and truncation-by-death can arise in randomized clinical trials; for example, in a cancer prevention trial, an outcome such as cancer severity is undefined for individuals who do not develop cancer. Restricting analysis to a subpopulation selected...

Noncompliance with assigned treatment is an important problem of randomized clinical trials. In this situation, the structural mean model (SMM) approach focuses on the average treatment effect among patients actually treated (ATT). In contrast, the principal stratification (PS) approach...